WO2015105437A1 - Supplémentation en nutriments multiples - Google Patents

Supplémentation en nutriments multiples Download PDF

Info

Publication number
WO2015105437A1
WO2015105437A1 PCT/SE2013/000186 SE2013000186W WO2015105437A1 WO 2015105437 A1 WO2015105437 A1 WO 2015105437A1 SE 2013000186 W SE2013000186 W SE 2013000186W WO 2015105437 A1 WO2015105437 A1 WO 2015105437A1
Authority
WO
WIPO (PCT)
Prior art keywords
vitamin
source
composition
disease
potassium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/SE2013/000186
Other languages
English (en)
Inventor
Per-Arne OCKERMAN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to PCT/SE2013/000186 priority Critical patent/WO2015105437A1/fr
Publication of WO2015105437A1 publication Critical patent/WO2015105437A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A61K31/015—Hydrocarbons carbocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07—Retinol compounds, e.g. vitamin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/30—Copper compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/315—Zinc compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A61K31/51—Thiamines, e.g. vitamin B1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/18—Iodine; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/32—Manganese; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/34—Copper; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/42—Phosphorus; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/60—Fish, e.g. seahorses; Fish eggs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/45—Ericaceae or Vacciniaceae (Heath or Blueberry family), e.g. blueberry, cranberry or bilberry
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Definitions

  • CVD cardiovascular disease
  • CVD cardiovascular disease
  • a typical western diet contains energy-rich, but nutrient-poor food with a high level of sugar and fat. Production methods have been directed more at volume than nutritional value. Many persons, therefore, get less of essential nutrients and more of calories than recommendable. Other factors may increase the risk, e.g. malabsorption, genetic polymorphism, increased demand by stress and disease, loss of appetite. Biochemical differences exist between individuals and may mean increased need, not satisfied by RDI-doses. Statistically, if the need among the population is according to a normal curve, it is clear that 2.5% lies outside each end of the curve. For 40 essential nutrients this means that the probability that a certain person, who gets RDI of all the nutrients, gets enough of all 40 nutrients, is only36%.
  • Vitamins A large number of studies have shown or failed to show an influence of some vitamins, e.g. C, D, E, K, on the risk for CVD (10-14).
  • Multivitamin supplements do not decrease CVD-risk as a conclusion from treatment by only three vitamins of the known twelve?
  • vitamins work in cooperation with other cofactors, such as trace elements and minerals, in a very large number of essential enzyme reactions, not to mention other nutrients, e.g. fatty acids and amino acids, that might be of influence.
  • Treatment e.g. fatty acids and amino acids
  • the first 85 patients were given all essential vitamins, trace elements and minerals, several antioxidants, fish oil, l-arginin, N-acetyl-cystein and probiotics in doses as described in ref.l.
  • PWVao Pulse wave velocity
  • AlXbrach augmentation index
  • cSBP brachial and central
  • AIXbrach Function of peripheral arteries and cardio-vascular risk.
  • cSBP Puts a load on the heart, if higher than SBPbrach.
  • Pulse wave velocity Pulse wave velocity (PWVao), augmentation index (AlXbrach), brachial and central blood pressure and Diastolic Area Index (DAI) before and after two months of treatment by MultiNutrient Supplementation In 40 patients.
  • PWVao Pulse wave velocity
  • AlXbrach augmentation index
  • DAI Diastolic Area Index
  • **DAl Indicates perfusion of the coronary arteries. Discussion.
  • Zinc decreases C-reactive protein, lipid peroxidation, and
  • CVD cardiovascular disease
  • CVD cardiovascular disease
  • a typical western diet contains energy-rich, but nutrient-poor food with a high level of sugar and fat. Production methods have been directed more at volume than nutritional value. Many persons, therefore, get less of essential nutrients and more of calories than recommendable. Other factors may increase the risk, e.g. malabsorption, genetic polymorphism, increased demand by stress and disease, loss of appetite. Biochemical differences exist between individuals and may mean increased need, not satisfied by RDI-doses. Statistically, if the need among the population is according to a normal curve, it is clear that 2.5% lies outside each end of the curve. For 40 essential nutrients this means that the probability that a certain person, who gets RDI of all the nutrients, gets enough of all 40 nutrients, is only36 . To this comes the above mentioned factors, that will diminish the probability even further (2).This reasoning would be an argument both for better diet and supplements.
  • Vitamins A large number of studies have shown or failed to show an influence of some vitamins, e.g. C, D, E, K, on the risk for CVD (10-14).
  • liver function The liver has an important function for the excretion of endo- and exogenous toxins. When its capacity is insufficient, free radicals increase CVD-risk. N-acetyl-cystein improves the detoxification capacity and has thereby a potential influence on CVD-risk (19).
  • Multivitamin supplements do not decrease CVD-risk as a conclusion from treatment by only three vitamins of the known twelve?
  • vitamins work in cooperation with other cofactors, such as trace elements and minerals, in a very large number of essential enzyme reactions, not to mention other nutrients, e.g. fatty acids and amino acids, that might be of influence.
  • PWVao Pulse wove velocity
  • AlXbrach augmentation index
  • cSBP brachial and central
  • PWVao Elasticity of the aortic wall and cardio-vascular risk.
  • AIXbrach Function of peripheral arteries and cardio-vascular risk.
  • cSBP Puts a load on the heart, if highe r than SBPbrach
  • Zinc decreases C-reactive protein, lipid peroxidation, and inflammatory cytokines in elderly subjects: a potential implication of zinc as an atheroprotective agent. Am J Clin Nutr. 2010;91(6):1634-41.
  • CVD cardio-vascular disease
  • CVD cardio-vascular disease
  • PWVao Pulse wave velocity
  • AlXbrach augmentation index
  • cSBP brachial and central
  • AlXbrach (Augmentation index, brachial):Function of peripheral arteries and cardio-vascular risk.
  • cSBP Central systolic blood pressure

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Divers modes de réalisation de l'invention concernent des compositions comprenant des vitamines, des minéraux et des oligo-éléments, des antioxydants, des acides aminés, des probiotiques et d'autres composants, ainsi que des procédés d'utilisation de telles compositions pour traiter ou prévenir des maladies associées au stress oxydatif, dont les maladies cardio-vasculaires.
PCT/SE2013/000186 2014-01-13 2014-01-13 Supplémentation en nutriments multiples Ceased WO2015105437A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/SE2013/000186 WO2015105437A1 (fr) 2014-01-13 2014-01-13 Supplémentation en nutriments multiples

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/SE2013/000186 WO2015105437A1 (fr) 2014-01-13 2014-01-13 Supplémentation en nutriments multiples

Publications (1)

Publication Number Publication Date
WO2015105437A1 true WO2015105437A1 (fr) 2015-07-16

Family

ID=53524172

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/SE2013/000186 Ceased WO2015105437A1 (fr) 2014-01-13 2014-01-13 Supplémentation en nutriments multiples

Country Status (1)

Country Link
WO (1) WO2015105437A1 (fr)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016046727A1 (fr) * 2014-09-23 2016-03-31 Dom Terry International S.R.L. Préparation prébiotique à base d'inuline
CN109125525A (zh) * 2017-06-16 2019-01-04 广州市康优元生物科技有限公司 防治心血管疾病的组合物及其制备方法和应用
CN110420225A (zh) * 2018-09-06 2019-11-08 澳汀斯（广州）生物医药科技有限公司 一种用于防治骨关节炎的组合物及其制备方法和应用
WO2023237688A1 (fr) * 2022-06-10 2023-12-14 Dsm Ip Assets B.V. Combinaisons comprenant de la vitamine c et lactobacillus rhamnosus
WO2023237686A1 (fr) * 2022-06-10 2023-12-14 Dsm Ip Assets B.V. Combinaisons comprenant de la vitamine c et du lactobacillus rhamnosus
WO2023237684A1 (fr) * 2022-06-10 2023-12-14 Dsm Ip Assets B.V. Combinaisons comprenant de la vitamine c et du lactobacillus rhamnosus
WO2023237689A1 (fr) * 2022-06-10 2023-12-14 Dsm Ip Assets B.V. Combinaisons comprenant de la vitamine c et du lactobacillus rhamnosus

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5776887A (en) * 1995-10-16 1998-07-07 Bristol-Myers Squibb Company Diabetic nutritional product having controlled absorption of carbohydrate
US20060127505A1 (en) * 2002-01-16 2006-06-15 David Haines Anti-inflammatory formulations
EP2374452A1 (fr) * 2008-12-05 2011-10-12 Ajinomoto Co., Inc. Composition nutritive
US20130095204A1 (en) * 2011-10-14 2013-04-18 Zeina Jouni Nutritional phytonutrient compositions
US20130224281A1 (en) * 2011-04-07 2013-08-29 United States Of America As Represented By The Administrator Of The National Aeronautics & Space Method and composition for ameliorating the effects for a subject exposed to radiation or other sources of oxidative stress

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5776887A (en) * 1995-10-16 1998-07-07 Bristol-Myers Squibb Company Diabetic nutritional product having controlled absorption of carbohydrate
US20060127505A1 (en) * 2002-01-16 2006-06-15 David Haines Anti-inflammatory formulations
EP2374452A1 (fr) * 2008-12-05 2011-10-12 Ajinomoto Co., Inc. Composition nutritive
US20130224281A1 (en) * 2011-04-07 2013-08-29 United States Of America As Represented By The Administrator Of The National Aeronautics & Space Method and composition for ameliorating the effects for a subject exposed to radiation or other sources of oxidative stress
US20130095204A1 (en) * 2011-10-14 2013-04-18 Zeina Jouni Nutritional phytonutrient compositions

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ÖCKERMAN, PER-ARNE: "Improvement of arterial stiffness by Multi-nutrient supplementation", JOURNAL OF ORTHOMOLECULAR MEDICINE, vol. 26, no. 4, 2011, pages 83 - 86 *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016046727A1 (fr) * 2014-09-23 2016-03-31 Dom Terry International S.R.L. Préparation prébiotique à base d'inuline
CN109125525A (zh) * 2017-06-16 2019-01-04 广州市康优元生物科技有限公司 防治心血管疾病的组合物及其制备方法和应用
CN110420225A (zh) * 2018-09-06 2019-11-08 澳汀斯（广州）生物医药科技有限公司 一种用于防治骨关节炎的组合物及其制备方法和应用
WO2023237688A1 (fr) * 2022-06-10 2023-12-14 Dsm Ip Assets B.V. Combinaisons comprenant de la vitamine c et lactobacillus rhamnosus
WO2023237686A1 (fr) * 2022-06-10 2023-12-14 Dsm Ip Assets B.V. Combinaisons comprenant de la vitamine c et du lactobacillus rhamnosus
WO2023237684A1 (fr) * 2022-06-10 2023-12-14 Dsm Ip Assets B.V. Combinaisons comprenant de la vitamine c et du lactobacillus rhamnosus
WO2023237689A1 (fr) * 2022-06-10 2023-12-14 Dsm Ip Assets B.V. Combinaisons comprenant de la vitamine c et du lactobacillus rhamnosus

Similar Documents

Publication Publication Date Title
WO2015105437A1 (fr) Supplémentation en nutriments multiples
Kerley A review of plant-based diets to prevent and treat heart failure
Houston The role of cellular micronutrient analysis, nutraceuticals, vitamins, antioxidants and minerals in the prevention and treatment of hypertension and cardiovascular disease
El Sohaimy Functional foods and nutraceuticals-modern approach to food science
US5976548A (en) Nutritional supplement composition and use
US11963992B2 (en) Multi-nutrient supplement composition and uses thereof
Lee et al. Reduced medication use and improved pulmonary function with supplements containing vegetable and fruit concentrate, fish oil and probiotics in asthmatic school children: a randomised controlled trial
Sagris et al. Nutrition, dietary habits, and weight management to prevent and treat patients with peripheral artery disease
Paoli et al. Not only protein: dietary supplements to optimize the skeletal muscle growth response to resistance training: the current state of knowledge
Alexiadou et al. Nuts: anti-atherogenic food?
Allahyari et al. The efficacy of dietary supplements on health status and performance of football players: a systematic review
WO1998000024A1 (fr) Composition et utilisation de complements nutritionnels
McCullough et al. Nutritional Deficiencies and Sarcopenia in Heart Failure: A Therapeutic Opportunity to Reduce Hospitalization and Death.
Naghedi-Baghdar et al. Effect of a functional food (vegetable soup) on blood rheology in patients with polycythemia
Houston The treatment of hypertension with nutrition, nutritional supplements, and lifestyle
Bhat Bioactive natural products as dietary supplements: Exploring the role of plant and animal-derived compounds
Wójtowicz et al. The Importance of Supplementation in Vegan and Vegetarian Diets for Adults
Li et al. Dietary supplement use in patients with cardiovascular disease
Yanru et al. Recent Nutraceutical Interventions for Hypertension: A Comprehensive Review of Randomized Clinical Evidence
Al-Okbi et al. Urgent Need of Nutritional Strategy and Innovated Functional Foods for Athletes Health and Fitness
Thakur et al. Nutraceuticals and Suboptimal Health: The Relationship and Significance
Obi Nutritional interventions in reducing morbidity and mortality in people with human immunodeficiency virus
da Silveira et al. Nutrition Therapy for Adults with HIV on ART
Kesharwani et al. Nutraceuticals as Food Supplements for Athletes
Shi et al. Global hotspots and trends of nutritional supplements for sick populations from 2000 to 2024

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13900851

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 13900851

Country of ref document: EP

Kind code of ref document: A1